TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06948981: A Single-arm, Open-label, Phase I/II Clinical Study of GT719 Injection for Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Sponsor: Grit Biotechnology · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06948981 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06948981 Rescue Dossier →